Atomoxetine hydrochloride

Analytical reagents were all employed without further purification. Mash Premiere for Pharmaceutical Industries (Badr city, Egypt) provided pharmaceutical grade atomoxetine hydrochloride and p-chloranil (Sigma Chemical Co., USA) 200 mg of p-chloranil were dissolved in a 100 mL volumetric flask with acetonitrile as the solvent to create 0.2% w/v. 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) (Sigma Chemical Co., USA) 0.3% w/v is produced by combining 300 mg of DDQ with acetonitrile and dissolving it in a 100 mL standard flask. El Nasr Chemical Co. provided the ethanol, methanol, acetonitrile, 1,4-dioxane, and dimethylformamide that were purchased (Abu Zaabal, Egypt).

Animals received each drug/dose in a random order to protect against order effects, with at least 3 days between treatment days to allow for sufficient washout. Atomoxetine hydrochloride was obtained from Sigma (Y0001586) and was dissolved in 0.9% NaCl (saline) which was administered via intraperitoneal injection at a dose of either 5 mg/kg or 10 mg/kg 30 min prior to the start of the Go/NoGo test. D-amphetamine hemisulfate was obtained from Sigma (A5880 and was dissolved in 0.9% NaCl (saline) which was administered via intraperitoneal injection at a dose of either 1 mg/kg or 2.5 mg/kg 10 min prior to the start of the Go/NoGo test^{22 (link),54 (link)}). Additionally, a HcrtR1 antagonist was obtained from Boehringer Ingelheim (patent WO2017/178339) and was dissolved in 0.5% hydroxyethylcellulose (Sigma, 525944) and 0.015% Tween 80 (Sigma, P1754) in water which was administered via oral gavage at a dose of either 2.5 mg/kg, 7.5 mg/kg, or 12.5 mg/kg. In addition to the 7 drug/dose groups, two control groups were included in which mice received either an intraperitoneal injection of saline 10 min prior to the start of the Go/NoGo test or received the vehicle solution used to administer the HcrtR1 compound via oral gavage 60 min prior to the start of the Go/NoGo test.